These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 32398324)

  • 1. Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
    Lampert EJ; Zimmer A; Padget M; Cimino-Mathews A; Nair JR; Liu Y; Swisher EM; Hodge JW; Nixon AB; Nichols E; Bagheri MH; Levy E; Radke MR; Lipkowitz S; Annunziata CM; Taube JM; Steinberg SM; Lee JM
    Clin Cancer Res; 2020 Aug; 26(16):4268-4279. PubMed ID: 32398324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
    Lheureux S; Oaknin A; Garg S; Bruce JP; Madariaga A; Dhani NC; Bowering V; White J; Accardi S; Tan Q; Braunstein M; Karakasis K; Cirlan I; Pedersen S; Li T; Fariñas-Madrid L; Lee YC; Liu ZA; Pugh TJ; Oza AM
    Clin Cancer Res; 2020 Aug; 26(16):4206-4215. PubMed ID: 32444417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
    Lee JM; Cimino-Mathews A; Peer CJ; Zimmer A; Lipkowitz S; Annunziata CM; Cao L; Harrell MI; Swisher EM; Houston N; Botesteanu DA; Taube JM; Thompson E; Ogurtsova A; Xu H; Nguyen J; Ho TW; Figg WD; Kohn EC
    J Clin Oncol; 2017 Jul; 35(19):2193-2202. PubMed ID: 28471727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
    Domchek SM; Postel-Vinay S; Im SA; Park YH; Delord JP; Italiano A; Alexandre J; You B; Bastian S; Krebs MG; Wang D; Waqar SN; Lanasa M; Rhee J; Gao H; Rocher-Ros V; Jones EV; Gulati S; Coenen-Stass A; Kozarewa I; Lai Z; Angell HK; Opincar L; Herbolsheimer P; Kaufman B
    Lancet Oncol; 2020 Sep; 21(9):1155-1164. PubMed ID: 32771088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
    Shah PD; Wethington SL; Pagan C; Latif N; Tanyi J; Martin LP; Morgan M; Burger RA; Haggerty A; Zarrin H; Rodriguez D; Domchek S; Drapkin R; Shih IM; Smith SA; Dean E; Gaillard S; Armstrong D; Torigian DA; Hwang WT; Giuntoli R; Simpkins F
    Gynecol Oncol; 2021 Nov; 163(2):246-253. PubMed ID: 34620496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
    Zimmer AS; Nichols E; Cimino-Mathews A; Peer C; Cao L; Lee MJ; Kohn EC; Annunziata CM; Lipkowitz S; Trepel JB; Sharma R; Mikkilineni L; Gatti-Mays M; Figg WD; Houston ND; Lee JM
    J Immunother Cancer; 2019 Jul; 7(1):197. PubMed ID: 31345267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
    Mutch D; Voulgari A; Chen XM; Bradley WH; Oaknin A; Perez Fidalgo JA; Montosa FG; Herraez AC; Holloway RW; Powell MA; Nowicka M; Schaefer G; Merchant M; Yan Y
    Cancer; 2024 Jun; 130(11):1940-1951. PubMed ID: 38288862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
    Matulonis UA; Wulf GM; Barry WT; Birrer M; Westin SN; Farooq S; Bell-McGuinn KM; Obermayer E; Whalen C; Spagnoletti T; Luo W; Liu H; Hok RC; Aghajanian C; Solit DB; Mills GB; Taylor BS; Won H; Berger MF; Palakurthi S; Liu J; Cantley LC; Winer E
    Ann Oncol; 2017 Mar; 28(3):512-518. PubMed ID: 27993796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
    Liu JF; Barry WT; Birrer M; Lee JM; Buckanovich RJ; Fleming GF; Rimel BJ; Buss MK; Nattam SR; Hurteau J; Luo W; Curtis J; Whalen C; Kohn EC; Ivy SP; Matulonis UA
    Ann Oncol; 2019 Apr; 30(4):551-557. PubMed ID: 30753272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
    Liu JF; Barry WT; Birrer M; Lee JM; Buckanovich RJ; Fleming GF; Rimel B; Buss MK; Nattam S; Hurteau J; Luo W; Quy P; Whalen C; Obermayer L; Lee H; Winer EP; Kohn EC; Ivy SP; Matulonis UA
    Lancet Oncol; 2014 Oct; 15(11):1207-14. PubMed ID: 25218906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
    McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
    Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
    Liu JF; Tolaney SM; Birrer M; Fleming GF; Buss MK; Dahlberg SE; Lee H; Whalen C; Tyburski K; Winer E; Ivy P; Matulonis UA
    Eur J Cancer; 2013 Sep; 49(14):2972-8. PubMed ID: 23810467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
    Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U
    Lancet Oncol; 2014 Jul; 15(8):852-61. PubMed ID: 24882434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.
    Matulonis UA; Penson RT; Domchek SM; Kaufman B; Shapira-Frommer R; Audeh MW; Kaye S; Molife LR; Gelmon KA; Robertson JD; Mann H; Ho TW; Coleman RL
    Ann Oncol; 2016 Jun; 27(6):1013-1019. PubMed ID: 26961146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
    Poveda AM; Davidson R; Blakeley C; Milner A
    Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.
    Tan TJ; Sammons S; Im YH; She L; Mundy K; Bigelow R; Traina TA; Anders C; Yeong J; Renzulli E; Kim SB; Dent R
    Clin Cancer Res; 2024 Apr; 30(7):1240-1247. PubMed ID: 38236575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
    Liu JF; Xiong N; Wenham RM; Wahner-Hendrickson A; Armstrong DK; Chan N; O'Malley DM; Lee JM; Penson RT; Cristea MC; Abbruzzese JL; Matsuo K; Olawaiye AB; Barry WT; Cheng SC; Polak M; Swisher EM; Shapiro GI; Kohn EC; Ivy SP; Matulonis UA
    Gynecol Oncol; 2024 Aug; 187():105-112. PubMed ID: 38759516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.